NDA 217513 · Novartis
Mekinist
Trametinib, Trametinib Dimethyl Sulfoxide · Oral
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Mar 16, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
275
17 Phase 3, 43 recruiting
FAERS reports
24,319
17,696 serious, 5,169 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 7, 2026.
MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal...
Mechanism: Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. Trametinib inhibits cell growth of various BRAF V600 mutation-positive tumors in vitro and in vivo. Trametinib and dabrafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 7, 2025 Supplement 5 · Efficacy OrphanLetterLabel
- Mar 16, 2023 Original approval · Type 5 - New Formulation or New Manufacturer · priority review OrphanLabelLetterReview
3 products under this application
- MEKINIST · TRAMETINIB 4.7MG · SOLUTION, ORAL · Prescription
- MEKINIST · TRAMETINIB DIMETHYL SULFOXIDE EQ 0.05MG BASE/ML · SOLUTION, ORAL · Prescription
- MEKINIST · TRAMETINIB 2MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trametinib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Pan Tumor Rollover StudyRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03899155 · 1,500 participants (planned) · Start Aug 9, 2019 · Primary completion Aug 25, 2029
Drug: Nivolumab; Ipilimumab and 17 more · For: Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Lynwood, California · 410 sites in all
- Molecularly Tailored Therapy in Advanced Pancreatic CancerPivotal-lookingNot yet recruiting
Herlev HospitalAcademic, hospital or other
NCT07802418 · 1,200 participants (planned) · Start Oct 2026 · Primary completion Jun 2031
Drug: Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy and 1 more · For: Pancreatic Cancer
Sites: Aalborg, Denmark; Aarhus, Denmark; Herlev, Denmark · 4 sites in all
- Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01682083 · 870 participants · Start Jan 8, 2013 · Primary completion Jun 30, 2017
Drug: Dabrafenib; Trametinib and 1 more · For: Melanoma
Sites: Birmingham, Alabama; Tucson, Arizona; San Francisco, California · 168 sites in all
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolPivotal-lookingRecruiting
Cancer Research UKAcademic, hospital or other
NCT05722886 · 825 participants (planned) · Start Mar 1, 2023 · Primary completion Oct 2029
Drug: Alectinib; Atezolizumab and 5 more · For: Haematological Malignancy; Solid Tumour
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Bristol, United Kingdom · 27 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia4,116
- death3,413
- malignant neoplasm progression2,070
- rash1,764
- fatigue1,538
- nausea1,512
- diarrhoea1,308
- chills1,303
- product use in unapproved indication1,091
- vomiting1,083
- off label use873
- headache771
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 360 |
| 2014 | 628 |
| 2015 | 1,693 |
| 2016 | 1,422 |
| 2017 | 1,760 |
| 2018 | 2,350 |
| 2019 | 2,676 |
| 2020 | 2,470 |
| 2021 | 2,414 |
| 2022 | 2,233 |
| 2023 | 2,150 |
| 2024 | 1,731 |
| 2025 | 1,525 |
| 2026 | 907 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mekinist (Trametinib Dimethyl Sulfoxide)
2024 spending
$207M
Beneficiaries
2,654
14,526 claims
Per beneficiary
$77,997
$399.06 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $113,841,286 |
| 2021 | $136,778,622 |
| 2022 | $159,068,731 |
| 2023 | $173,398,802 |
| 2024 | $207,005,041 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Long GV, Hauschild A, Santinami M, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Multicenter Study
- Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Atkins MB, Lee SJ, Chmielowski B, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S, Do Cao C, Zerdoud S, et al. · Clin Cancer Res 2023 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.
Bouffet E, Hansford JR, Garrè ML, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV, Hauschild A, Santinami M, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Robert C, Grob JJ, Stroyakovskiy D, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.